These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 10986900)

  • 1. [HIV protease inhibitors and interactions].
    Justesen US; Brøsen K; Pedersen C
    Ugeskr Laeger; 2000 Aug; 162(35):4677-81. PubMed ID: 10986900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double jeopardy: the hazards of drug-drug interactions.
    Flexner C
    Res Initiat Treat Action; 1998 Dec; 4(7):3-8. PubMed ID: 11366084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risks and synergies from drug interactions.
    Sahai J
    AIDS; 1996 Nov; 10 Suppl 1():S21-5. PubMed ID: 8970672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction between lopinavir/ritonavir and warfarin.
    Hughes CA; Freitas A; Miedzinski LJ
    CMAJ; 2007 Aug; 177(4):357-9. PubMed ID: 17698824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A further point about statins...
    Gilden D
    GMHC Treat Issues; 1998 Jun; 12(6):8. PubMed ID: 11365725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection.
    Fichtenbaum CJ; Gerber JG
    Clin Pharmacokinet; 2002; 41(14):1195-211. PubMed ID: 12405866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Anti-HIV drugs].
    Raffi F
    Rev Prat; 1999 Oct; 49(16):1763-71. PubMed ID: 10578607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protease inhibitor drug interactions.
    Rose E; Romeyn M
    BETA; 1997 Sep; ():29-38. PubMed ID: 11364696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and antiviral activities of the major metabolites of the HIV protease inhibitor ABT-378 (Lopinavir).
    Sham HL; Betebenner DA; Herrin T; Kumar G; Saldivar A; Vasavanonda S; Molla A; Kempf DJ; Plattner JJ; Norbeck DW
    Bioorg Med Chem Lett; 2001 Jun; 11(11):1351-3. PubMed ID: 11378352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1, 2, 3-current ways to fight HIV.
    Vazquez E
    Posit Aware; 1998; 9(6):31-3. PubMed ID: 11366478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations.
    Barry M; Gibbons S; Back D; Mulcahy F
    Clin Pharmacokinet; 1997 Mar; 32(3):194-209. PubMed ID: 9084959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protease inhibitor plasma concentrations in HIV antiretroviral therapy.
    Justesen US
    Dan Med Bull; 2008 Nov; 55(4):165-85. PubMed ID: 19232158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents.
    Hsu A; Granneman GR; Bertz RJ
    Clin Pharmacokinet; 1998 Oct; 35(4):275-91. PubMed ID: 9812178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug.
    Wire MB; Shelton MJ; Studenberg S
    Clin Pharmacokinet; 2006; 45(2):137-68. PubMed ID: 16485915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Saquinavir. Clinical pharmacology and efficacy.
    Vella S; Floridia M
    Clin Pharmacokinet; 1998 Mar; 34(3):189-201. PubMed ID: 9533981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tipranavir: a novel nonpeptidic protease inhibitor of HIV.
    King JR; Acosta EP
    Clin Pharmacokinet; 2006; 45(7):665-82. PubMed ID: 16802849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions.
    Dixit V; Hariparsad N; Li F; Desai P; Thummel KE; Unadkat JD
    Drug Metab Dispos; 2007 Oct; 35(10):1853-9. PubMed ID: 17639026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug interactions between HIV protease inhibitors and acid-reducing agents.
    Falcon RW; Kakuda TN
    Clin Pharmacokinet; 2008; 47(2):75-89. PubMed ID: 18193914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV protease inhibitors: pharmacologic and metabolic distinctions.
    Sommadossi JP
    AIDS; 1999 Sep; 13 Suppl 1():S29-40. PubMed ID: 10546783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential interactions between cholesterol lowering drugs and protease inhibitors.
    Notes Undergr; 1998; (No 37):8. PubMed ID: 11365822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.